We speculate that this may be attributed to small sample sizes, ethnic differences, and subjectivity in HER2 testing in these studies and further research is needed with larger sample size and more balanced data in multicenter setting to compare the NAC efficacy between HER2-zero and HER2-low in breast cancer. The gene discussed is ERBB2; the disease is breast carcinoma.